Statistical imputation of genotype data is an important technique for analysis of genome-wide association studies (GWAS). We have built a reference dataset to improve imputation accuracy for studies of individuals of primarily European descent using genotype data from the Hap1, Omni1, and Omni2.5 human SNP arrays (Illumina). Our dataset contains 2.5-3.1 million variants for 930 European, 157 Asian, and 162 African/African-American individuals. Imputation accuracy of European data from Hap660 or OmniExpress array content, measured by the proportion of variants imputed with R 2 >0.8, improved by 34%, 23% and 12% for variants with MAF of 3%, 5% and 10%, respectively, compared to imputation using publicly available data from 1,000 Genomes and International HapMap projects. The improved accuracy with the use of the new dataset could increase the power for GWAS by as much as 8% relative to genotyping all variants. This reference dataset is available to the scientific community through the NCBI dbGaP portal. Future versions will include additional genotype data as well as non-European populations.
Introduction
Genome-wide association studies (GWAS) have emerged as a successful strategy for the discovery of common single nucleotide polymorphism (SNP) markers associated with human diseases/traits 1 . The decreasing cost of commercial dense SNP arrays has enabled investigators to scan the genome and prioritize variants for confirmation of true signals amidst a large number of false positives 2 .
Hundreds of different loci in the genome have been conclusively associated with more than 100 distinct complex diseases and traits, ushering in a new age of discovery in human genetics 3 .
The first generation of commercial genotyping arrays was based on genetic variants annotated by the International Human HapMap project [4] [5] [6] as well as those in the NCBI dbSNP database. These arrays have targeted common SNP markers across the genome with the majority of variants with minor allele frequency (MAF) greater than 10%, though a small proportion of content included uncommon variants with MAF between 5 and 10% 7 . Between the bias due to array content and the larger sample sizes needed to detect uncommon variants, it is not surprising that the majority of markers identified in GWAS have been common variants. The proliferation of meta-analyses between existing scans, together with larger replication sets, have shifted the focus of the field from the identification of a few regions to the discovery of comprehensive sets of common variants associated with one or more human diseases or traits [8] [9] [10] [11] .
Until recently, genome-wide association studies have been conducted with either the "HumanHap" series of Illumina, Inc. or the Affymetrix 6.0, genotyping up to 1,000,000 SNPs. The 1000
Genome Project has laid the foundation for annotating many more common (MAF > 5%) and uncommon SNPs (MAF between 1% and 5%) in multiple continental reference populations [4] [5] [6] . Since commercial vendors have transitioned to new denser content arrays that can genotype up to 5,000,000 SNPs, the lack of overlap between commercial arrays will require GWAS investigators to depend upon statistical genotype imputation techniques for analysis across vendor arrays as well as between different generations of assays by the same vendor. For instance, Illumina, Inc. has recently discontinued and replaced the "HumanHap" assays with a new series of "Omni" assays that contain 720,000-5,000,000 SNPs assays with content that is substantially different from the earlier series. Similarly, Affymetrix has released the Axiom assay, which allows similar genotyping of millions of SNPs based on population-customized content.
Statistical imputation of genotype data [12] [13] [14] [15] is an important technique that uses patterns of linkage disequilibrium observed in a reference set to computationally predict additional genetic variants in silico.
Imputed genotypes may be tested for association with phenotypes, but also enable the combining of genotype data typed on SNP arrays with different content, as well as the use of methods that are intolerant of missing data. The accuracy of genotype imputation depends on the sample size of the reference set, the comprehensive nature of the SNP coverage, data quality and the comparability of the reference set to the study population(s) with respect to the underlying population substructure [16] [17] [18] . Currently, the most popular reference sets are the publicly available International HapMap and 1000 Genomes datasets [4] [5] [6] .
While these resources are valuable for imputing a sizeable fraction of common SNPs (MAF > 10%), they may not be optimal for imputing data for the next generation of GWAS arrays.
Since most studies have been conducted on first generation commercial arrays with less dense content (e.g., optimizing coverage for SNPs with MAF > 10%), we have developed a resource to enable use of older array data to impute new content as well as to enhance the ability to combine studies across platforms. Furthermore, the resource can address the performance of imputation of common and now uncommon variants not represented on first generation SNP arrays. The Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute (NCI) has generated a dataset, now deposited in dbGaP, which is expected to expand to increase SNP genotype content and to incorporate additional data from non-European populations.
Results
The DCEG Imputation Reference Set includes; (1) 728 cancer-free individuals of European descent from three large prospectively sampled studies [19] [20] [21] [22] (Table 1) . During the quality control process, we removed 90 non-founders and two additional subjects forming related pairs from the HapMap set. The relationships and extent of overlapping content among the 2.8 million SNPs and the Illumina arrays (as portrayed in the commercial manifests) and 1000 Genomes and HapMap 3 data are shown in Figure 1a ; the OmniExpress content simulated from 2.8 million SNPs of DCEG Reference Set and the content overlapping with 1000 Genomes and HapMap 3 data are shown in Figure 1b . In the DCEG Reference Set, the MAF distribution for the Omni2.5 array is shown per population in Figure 2 . It is notable that over 1 million uncommon (or rare) SNPs (MAF < 10%) were observed across different populations on the Omni2.5 array; the largest number was observed in Asians while the smallest number is in African-Americans. Since the full content of the OmniExpress array is contained within the Omni1 array and the OmniExpress is less expensive, we have reported our analysis using the OmniExpress content only throughout the manuscript.
We compared the imputation performance of the DCEG Reference Set to the International
HapMap and 1000 genome reference sets, which were available from the IMPUTE2 website (URL below). Our approach to measuring imputation performance is based on the comparison of directly genotyped SNPs and probabilistic imputed genotypes (using both IMPUTE2 13 Accuracy was specifically assessed using the subset of 2 million SNPs with MAF > 1%.
Across the spectrum of MAFs for Illumina Hap660 and OmniExpress, we observed substantial improvement in imputation accuracy when using our reference panel compared to the combination of 1000 Genomes and HapMap data. We randomly selected 60 samples of European ancestry and imputed to the full set of 2.8 million SNPs, out of which 2 million SNPs with MAF > 1% were applicable for the evaluation of imputation performance ( Figure 3 and also more detailed R 2 distribution by MAF is shown in Figure 4 ). Accuracy in the European data from Hap660 or OmniExpress array content, measured by the proportion of variants imputed with R 2 >0.8, improved by 34%, 23% and 12% for variants with MAF of 3%, 5% and 10%, respectively. For the combined reference from DCEG, 1000 Genomes, and HapMap 3 data we observed slightly lower performance when imputing from the OmniExpress content to the full set and when combined, we observed no appreciable improvement ( Figure 5 ). We achieved similar results for all of these analyses using both the IMPUTE2 and BEAGLE imputation programs 12 .
We suspected that the matching of populations between inference and reference sets could be an important factor in overall accuracy. We explored different SNPs differ. Since the accuracy of imputation is also based on sample size, we observed a gradual improvement in accuracy as sample size increased from 50 to 800 ( Figure 8 ). Moreover, the effect was more pronounced for uncommon SNPs between 5 and 10%, whereas for SNPs above 10% the effect on the performance was less notable. The presumed return on investment for SNPs with lower MAF begins to diminish even at sample sizes of 600 and 800, an asymptotic behavior explored elsewhere 24 .
Although the current build of the DCEG reference Set is primarily intended for use in European populations, we tested the accuracy of imputing OmniExpress data on an African-American set from the Multi-Ethnic Cohort (MEC) study 25 . Accuracy was less optimal for African Americans, but still superior to the publicly available reference data. As seen in Figure 9 , there was an improvement in performance for SNPs above 3-5% when the reference set included 98 African-American samples from PLCO and the HapMap YRI samples. It is also notable that the performance was better for the combined set than with only the African Americans in PLCO ( Figure 9 ). For the two sets, the STRUCTURE plot shows a comparable distribution of admixture coefficients for the African-Americans along the axis between EUR and AFR ( Figure 10 ). A comparison of the overall imputed SNPs (~2 million when using our reference set versus 1.38 million derived from 1000 Genome plus HapMap3) indicates an advantage of the DCEG Reference Set with MAF > 3%. The R 2 curve crossed over at 3% in MAF, which could be due to a substantial proportion of Omni2.5 SNPs with MAF < 3% that had to be imputed when using the DCEG set compared to the combined 1000 Genomes and HapMap set (which included more SNPs < 3% in total). When the common set of 1.38 million SNPs is compared, the performance improvement is consistent across all ranges of MAF, which was not clearly observed in the European populations ( Figure   3 ). Additional studies are needed to investigate these observations for African-Americans and perhaps other admixed populations that also include a substantial European contribution.
We compared estimates of power to detect associations in GWAS when SNPs are imputed and when they are directly genotyped. With imputation based on the DCEG reference set and 1000
Genomes/HapMap 3, a GWAS can be expected to detect 92.9% and 84.7%, respectively, of those associations discovered by direct genotyping when using the Hap660. The relative power from the DCEG reference set and 1000 Genomes/HapMap 3 were 93.9% and 86.2%, respectively, when using the OmniExpress based on the model of Park et al. 10 . These results suggest that new reference set improves the power for GWAS by a small, but noticeable, margin.
Discussion
In this report we show that a new public resource, the DCEG Reference set, performs better than the standard reference data sets, 1000 Genome Project and HapMap 3, for the imputation of common and uncommon SNPs, particularly in populations of European background. The improvement in imputation is evident in both forward and backward scenarios, namely from the earlier generation arrays to more dense arrays and for complementary arrays. Our data suggest that there are distinct advantages for the use of genotyped data compared to low pass sequence coverage with respect to the accuracy of imputation, which has implications for efficient GWAS studies. While low pass sequencing data may capture more variants, the cumulative effects of both higher false-positive and -negative rates may have a suboptimal effect on the accuracy of imputation of common and uncommon SNPs. Still, we show that there are advantages to imputation using a dataset with validated assays.
Our data set is particularly useful for investigators to conduct GWAS with a hybrid of data generated across arrays or between distinct generations of the same vendor (Hap660 and OmniExpress) using genotype imputation techniques to discover promising regions that will require confirmation in follow-up studies 2 . Since many GWAS share cases and controls, the use of our dataset should facilitate the approach of shared controls of similar or comparable population background, perhaps even across platforms on economic and genetic grounds.
Since imputation accuracy depends on the similarity in population substructure between reference and study populations, we examined the interchangeability of the three similar, but not identical European populations. In our analysis of the DCEG Reference Set, we encountered two unexpected and notable results. First, we were surprised to observe that for common SNPs, there was little impact of a reference population from Finland, clearly mismatched, with two cohorts drawn from across the continental USA (e.g., CPSII and PLCO) ( Figure 7 ). This suggests that for common variants a reference set of sufficiently larger size can adequately capture common SNPs when there is a small but real discrepancy in population genetics history. This could enable investigators to proceed with imputation without additional genotyping in related but not identical populations. In the second instance, although overall performance of imputation was less optimal for African Americans, we observed that a sufficiently large sample set of European subjects can improve imputation in African-Americans, beyond the utility of the PLCO African
American set, suggesting the value of the larger sample size of European subjects ( Figure 9 ). This could have an impact on the design of future studies in other populations with distinct substructures. Despite the fact that a subset of MAFs may differ, longer haplotypes could still be useful for imputation of common and uncommon variants. Although frequencies of variants may differ among population groups and subpopulations, our findings suggest that genotype imputation is relatively robust to these differences provided that a sufficient number of matching haplotypes appear in the reference data. In the future, larger sample sizes should be useful to determine imputation performance, particularly across the spectrum of lower MAFs.
We tested imputing OmniExpress data from European individuals with a reference dataset that combined the DCEG and 1,000 Genomes and HapMap references and observed no increase in accuracy over that was achieved using the DCEG Reference alone. This finding suggests that there are distinct advantages to using SNP array data compared to low pass sequence coverage with respect to the accuracy of imputation and has implications for efficient GWAS studies. One possible explanation is that SNP array and low-pass sequence variant data have distinct patterns of non-random errors. While suboptimal for imputation, it may also be necessary to preserve these errors when combining directly genotyped and imputed data in order to recapitulate the patterns of differential misclassification and perhaps retain statistical validity for association testing. Thus, SNP array data should be superior for imputation of genotypes obtained from SNP arrays, though not necessarily superior at imputing the true genotypes.
While low pass sequencing data may capture more variants, the cumulative effects of both higher falsepositive and -negative rates may also decrease imputation accuracy.
In conclusion, our study has shown the utility of the new DCEG Reference Set and its advantage for imputation of common and uncommon SNPs, making it a valuable resource for next-generation GWAS with denser chips in new populations. In turn, it is likely that even larger sample sizes will be needed for reference sets to explore SNPs with MAF at or below 1%. The DCEG Reference set has been released to the Database of Genotypes and Phenotypes (dbGaP) as Build 1. We plan to release subsequent builds expanding the number of subjects from diverse populations and adding new genotype content from the Affymetrix 6.0, Omni5 arrays, and future commercial products.
Materials and Methods

DNA Samples and Other data sources
906 subjects were chosen from two clinical trials and 2 prospective cohorts, Alpha-Tocopherol, [27] [28] were genotyped separately at USC with the Illumina HumanHap1 and the 2.5 arrays as a test set to evaluate the performance of the imputation of African American subjects in our reference set which includes 98 African American samples from the PLCO. Ancestry was estimated based on a set of informative SNPs 29 using GLU struct.admix module;
Genotyping and quality control
the HapMap build 27 CEU, YRI, ASA (JPT+CHB) samples were used as three continental reference populations. The detected ancestry is concordant with self-reported ethnicity except for two self-described African-American subjects, for whom the data indicate less than 15% non-CEU ancestry, and thus were considered to be CEU ancestry for this study ( Figure 10 ). Identity by descent (IBD) was estimated using the GLU qc.ibds module for all pair-wise comparisons to search for both expected and unexpected relatedness among the data set.
We also excluded subjects and loci with discordance rates greater than 1% after merging the genotypes generated from different arrays, resulting in exclusion of five subjects (2 ATBC, 1 CPSII and 2 PLCO). The merged data of array per subject resulted in the exclusion of a number of loci: 9,662 from the ATBC, 6,134 from the CPSII and 10,526 from the PLCO data sets. Assays from Illumina Hap1, Omni1-Quad, Omni2.5 arrays were harmonized based on the locus meta-data of 1000 Genomes June 2010 release and HapMap 3 release 2. Also excluded are an additional 942 loci with incompatible alleles (either matching directly or by reverse complementing) between our data and the public reference data, and additional 644 loci duplicated on Illumina arrays.
Imputation Scenarios
We chose IMPUTE2 to conduct all analyses because of its speed and the built-in sliding window user interface 13 . We conducted selected analyses with BEAGLE in parallel (using all default configuration and the same sliding window) 12 . Both programs performed very similarly, with IMPUTE2 slightly better than Beagle especially for the loci with MAF < 10%.
We investigated the effect of our new reference set (728 subjects of European ancestry from http://mathgen.stats.ox.ac.uk/impute/data_download_1000G_pilot_plus_hapmap3.html); and (3) the union of the DCEG reference set and the 1000 Genomes/HapMap 3 data sets. Accuracy was specifically assessed using the subset of 2.0 million SNPs with MAF >1%. In an exploration of the effect of population structure on the imputation accuracy, we evaluated imputation from content on Illumina OmniExpress to the Omni 2.5 SNPs using a subset (202 ATBC, 202 CPSII or 202 CEU+TSI) to impute genotypes of 255 PLCO samples of European ancestry. For testing the effect of reference size on imputation, the overall combined set of 930 samples was used to assess imputation accuracy in comparison to subsets (50, 100, 200, 400, 600 and 800 randomly selected samples) against a fixed set of 100, randomly chosen. In a preliminary exploration of the utility of the data set in other populations, we evaluated imputation in 94 African Americans drawn from the Multi-Ethnic Cohort, using the OmniExpress content to impute the remaining SNPs on the Omni 2.5.
The metric, allelic dosage based R 2 value, was calculated for each locus by comparing the imputed genotype dosage with the actual assayed genotypes for the inference set. Dosage R 2 is a convenient measure of imputation accuracy since its inverse is related to the decrease in power for casecontrol association tests. Another advantage to this measure is that it is applicable to low frequency variants, where simpler genotype concordance based measurements become increasingly insensitive. For example, a SNP with a minor allele frequency of 1% achieves a 99% concordance rate by assigning all genotypes to homozygous major allele. In our comparisons, the focus is on GWAS study power rather than purely on imputation accuracy; consequently, directly genotyped SNPs within the Hap660 and
OmniExpress subsets are assigned a squared-correlation coefficient R 2 =1. The curve of R 2 > 0.8 for each MAF bin is represented in scatter plots.
Power Estimate
Power calculations assumed a case/control study with the 10,000 individuals divided equally between the two groups. Associations were assumed to be tested by the score statistic. For SNP j, under the null hypothesis of no association, we assumed the test statistic, S j , was distributed according to a noncentral chi-square distribution with 1df. Let t α be 1-10 -7 quantile for this distribution. For SNP j, under the alternative hypothesis, we assumed that S j was distributed according to a noncentral chi-square distribution,χ 2 ηj , with noncentrality parameter η j and 1 df. The potential power for SNP j is the P(χ 2 ηj > t α ) . The estimated power for a GWAS is the average of the potential power across all SNPs. To calculate η j , we assumed that disease risk followed an additive genetic model and randomly selected an OR based on the distribution described in Park et al 10 . When calculating the power for SNP j in the scenario using imputation, the value of η j presuming direct genotyping needed to be multiplied by R 2 j for those SNPs not on the Hap660 or OmniExpress.
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